# Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR

> **NCT00412191** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 180 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lamotrigine

## Key facts

- **NCT ID:** NCT00412191
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-06
- **Primary completion:** 2007-04-27
- **Final completion:** 2007-04-27
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2017-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412191, "Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00412191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*